ArticleHereditas2025
Local anesthetic ropivacaine inhibits non-small cell lung cancer progression by modulating the hsa_circ_0001320/miR-518a-5p axis.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigated the possible mechanisms by which ropivacaine influences the progression of non-small cell lung cancer (NSCLC).
methodsPlasmid vectors or oligonucleotides interfering with circ_0001320 or miR-518a-5p were transfected into ropivacaine-treated NSCLC cells, and circ_0001320 and miR-518a-5p levels were detected by RT-qPCR. Cell proliferation was assessed using CCK-8, apoptosis via flow cytometry, and cell migration and invasion through Transwell assays. Finally, the binding sites of circ_0001320 and miR-518a-5p were verified by the bioinformatics website CircInteractome and dual luciferase reporter gene assay.
resultsExposure to ropivacaine resulted in the suppression of NSCLC cell proliferation, migration, invasion, and angiogenesis, while inducing apoptosis. Ropivacaine elevated circ_0001320 expression. Circ_0001320 downregulation resulted in a reduced efficacy of ropivacaine in inhibiting NSCLC progression. Interestingly, circ_0001320 targeted miR-518a-5p and inhibited its expression. It was possible to limit the effects of downregulation of circ_0001320 on NSCLC progression by downregulating miR-518a-5p.
conclusionRopivacaine inhibits NSCLC progression via the circ_0001320/miR-518a-5p axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.